Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Peripheral blood lymphocyte dynamics and viral kinetics in patients with chronic active hepatitis B virus infection treated by tenofovir.

Arasli M, Ustundag Y, Delikanli B, Harmandar F, Buyukuysal C.

Hepatogastroenterology. 2012 May;59(115):851-7. doi: 10.5754/hge11580.

PMID:
22193343
2.

Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients.

You J, Sriplung H, Geater A, Chongsuvivatwong V, Zhuang L, Li YL, Lei H, Liu J, Chen HY, Tang BZ, Huang JH.

BMC Infect Dis. 2008 Sep 22;8:123. doi: 10.1186/1471-2334-8-123.

3.

Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.

Li CZ, Hu JJ, Xue JY, Yin W, Liu YY, Fan WH, Xu H, Liang XS.

World J Gastroenterol. 2014 Jul 28;20(28):9486-96. doi: 10.3748/wjg.v20.i28.9486.

4.

Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.

Lau GK, Cooksley H, Ribeiro RM, Powers KA, Shudo E, Bowden S, Hui CK, Anderson J, Sorbel J, Mondou E, Rousseau F, Lewin S, Perelson AS, Locornini S, Naoumov NV.

Antivir Ther. 2007;12(5):705-18.

PMID:
17713154
5.

Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B.

Ma L, Cai YJ, Yu L, Feng JY, Wang J, Li C, Niu JQ, Jiang YF.

Antimicrob Agents Chemother. 2013 Mar;57(3):1304-11. doi: 10.1128/AAC.02181-12. Epub 2012 Dec 28.

7.

Regulatory T-cell responses in chronic hepatitis B patients treated with nucleos(t)ide analogs compared with healthy subjects and untreated infected individuals.

Chen LY, Zhu LY, Yang BS, Bi MR, Yan BZ, Wang W, Ma YJ.

Hepatogastroenterology. 2012 Nov-Dec;59(120):2582-6.

PMID:
22626879
8.

Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B.

Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, Zhao JM, Zhang B, Shi M, Ding X, Tang Z, Fu YX, Wang FS.

J Immunol. 2006 Jul 1;177(1):739-47.

9.

Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir.

Sherman AC, Trehanpati N, Daucher M, Davey RT, Masur H, Sarin SK, Kottilil S, Kohli A.

AIDS Res Hum Retroviruses. 2013 Apr;29(4):665-72. doi: 10.1089/AID.2012.0320. Epub 2013 Feb 11.

10.

Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate.

TrehanPati N, Kotillil S, Hissar SS, Shrivastava S, Khanam A, Sukriti S, Mishra SK, Sarin SK.

J Clin Immunol. 2011 Jun;31(3):509-20. doi: 10.1007/s10875-011-9509-7. Epub 2011 Feb 9.

PMID:
21305387
11.

[Studies about the level of CD4+ CD25+ regulatory T cells and relation between expression of Foxp3 and CD127 in peripheral blood of chronic HBV infection].

Deng M, Li MH, Liu SA, Liu F, Sang Y, Song SJ, Zang SF, Guan XP, Yao X, Wu XP, Cheng J, Xu DZ.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2010 Feb;24(1):21-3. Chinese.

PMID:
20848841
12.

Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.

van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, de Man RA.

J Viral Hepat. 2005 Jul;12(4):364-72.

PMID:
15985006
13.

Dissection of a circulating and intrahepatic CD4(+)Foxp3(+) T-cell subpopulation in chronic hepatitis B virus (HBV) infection: a highly informative strategy for distinguishing chronic HBV infection states.

Zhang M, Zhou J, Zhao T, Huang G, Tan Y, Tan S, Fu X, Niu W, Meng G, Chen X, Shang X, Liu D, Ni B, Wang L, Wu Y.

J Infect Dis. 2012 Apr 1;205(7):1111-20. doi: 10.1093/infdis/jis011. Epub 2012 Feb 21.

14.

Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.

Stephan C, Berger A, Carlebach A, Lutz T, Bickel M, Klauke S, Staszewski S, Stuermer M.

J Antimicrob Chemother. 2005 Dec;56(6):1087-93. Epub 2005 Nov 3.

15.
16.

Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B.

Güzelbulut F, Ovünç AO, Oetinkaya ZA, Senates E, Gökden Y, Saltürk AG, Sezikli M, Ozkara S, Cetinkaya F.

Hepatogastroenterology. 2012 Mar-Apr;59(114):477-80. doi: 10.5754/hge11426.

PMID:
21940383
17.

[Association between CD4+CD25+Foxp3+ regulatory T cells and serum transforming growth factor beta 1 in patients with chronic hepatitis B].

Yang GL, Xu LM, Yao HY, Wang HS, Jiang XL, Li W, Wang M, Zhou BP.

Zhonghua Gan Zang Bing Za Zhi. 2009 Nov;17(11):831-4. Chinese.

PMID:
19958642
18.

Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.

Lacombe K, Gozlan J, Boelle PY, Serfaty L, Zoulim F, Valleron AJ, Girard PM.

AIDS. 2005 Jun 10;19(9):907-15.

PMID:
15905671
19.

Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B.

Yang G, Liu A, Xie Q, Guo TB, Wan B, Zhou B, Zhang JZ.

Int Immunol. 2007 Feb;19(2):133-40. Epub 2006 Dec 20.

20.

Monitoring of CD95 and CD38 expression in peripheral blood T lymphocytes during active human cytomegalovirus infection after orthotopic liver transplantation.

Wang Y, Liu Y, Han R, Li Q, Yao Z, Niu W, Yuan Y, Tang Z, Zhu Z, Shen Z.

J Gastroenterol Hepatol. 2010 Jan;25(1):138-42. doi: 10.1111/j.1440-1746.2009.05966.x. Epub 2009 Oct 9.

PMID:
19817952
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk